Shield Therapeutics (GB:STX) has released an update.
Health Canada has approved Shield Therapeutics’ ACCRUFeR® as a prescription drug for iron deficiency anemia (IDA), marking a significant milestone for the company. Shield Therapeutics will receive a £250,000 payment and further revenue-based milestones and royalties from their partner, Kye Pharmaceuticals Inc., who will be launching the product in Canada. ACCRUFeR® is the only oral iron therapy approved in Canada and aims to address the unmet medical needs of patients with iron deficiency.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
